Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy

J Antimicrob Chemother. 2021 Nov 12;76(12):3322-3325. doi: 10.1093/jac/dkab316.

Nora Isberner¹, Ruth Van Daele^{2

3}, Hartwig Klinker¹, Sabrina Kraus⁴, Fatemeh Aghai¹, Greet De Vlieger⁵, Dirk Kuypers⁶, Yves Debaveye⁵, Isabel Spriet^{2

3}

¹ Division of Infectious Diseases, Department of Internal Medicine II, University of Würzburg Medical Center, Würzburg, Germany.
² Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
³ Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
⁴ Division of Hematology and Oncology, Department of Internal Medicine II, University of Würzburg Medical Center, Würzburg, Germany.
⁵ Clinical Division and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
⁶ Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium.

No abstract available

Publication types